134 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28613895	66	A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose.	Eli Lilly
27966948	86	Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.	Pharmaceutical
28337319	28	Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.	Universit£
27825552	152	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.	Takeda Pharmaceutical
27452283	241	Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.	Jadavpur University
26871660	68	Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.	San Raffaele Scientific Institute
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University of Minnesota
26263024	47	N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.	Universit£
26192023	71	SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.	Florida Atlantic University
25264600	64	Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.	Takeda Pharmaceutical
25415648	63	Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.	Eli Lilly
25265401	38	Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.	Universidad Ceu San Pablo
25192810	66	Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.	Takeda Pharmaceutical
24316668	34	Discovery of a benzimidazole series of ADAMTS-5 (aggrecanase-2) inhibitors by scaffold hopping.	Asahi Kasei Pharma
24071448	24	Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.	Universit£
24028490	46	O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.	University of Notre Dame
24044434	71	Selective arylsulfonamide inhibitors of ADAM-17: hit optimization and activity in ovarian cancer cell models.	UniversitÀ
23999043	1	Design and synthesis of MMP inhibitors with appended fluorescent tags for imaging and visualization of matrix metalloproteinase enzymes.	Mallinckrodt Pharmaceuticals
23810497	51	Hydantoin based inhibitors of MMP13--discovery of AZD6605.	Astrazeneca
23631440	44	Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core.	Florida State University
23453070	42	A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.	Asahi Kasei Pharma
23376997	53	Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.	Universit£
23287054	46	Sulphonamides: Deserving class as MMP inhibitors?	Indian Institute of Technology (Bhu)
23458498	24	Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.	Universit£
17275314	701	Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.	Pomona College
21669521	44	Selective non zinc binding inhibitors of MMP13.	Astrazeneca
21780776	40	Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.	Wroclaw University of Technology
21413800	56	A one-pot synthesis and biological activity of ageladine A and analogues.	Macquarie University
22737278	44	Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.	TBA
22175799	22	Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.	Alantos Pharmaceuticals
22342144	72	Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.	Panthera Biopharma
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
18251495	69	Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
18061445	103	Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).	Bristol-Myers Squibb Research and Development
17127067	21	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.	Instituto Superior T£Cnico
15713379	40	N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.	Universit£
15582436	7	N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.	Sejong University
12773042	195	Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
11472217	157	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Dupont Pharmaceuticals
15177439	96	Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.	Pfizer
22386984	67	In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.	Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl)
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22153941	140	Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.	Astrazeneca
22017539	75	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.	Boehringer Ingelheim Pharmaceuticals
22017477	35	Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.	Instituto Superior T£Cnico
22088955	33	Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.	Universit£
21548582	57	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.	University of Illinois At Chicago
21866961	28	Selective water-soluble gelatinase inhibitor prodrugs.	University of Notre Dame
20726512	282	Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.	Pfizer
21514700	56	Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.	Universit£
21536437	219	Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.	Astrazeneca
20638281	56	Structure and activity relationships of tartrate-based TACE inhibitors.	Merck Research Laboratories
21507637	102	MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.	Pfizer
21493063	67	MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.	Pfizer
21458257	87	2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.	Merck Research Laboratories
21417219	179	Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.	Central Pharmaceutical Research Institute
21300546	129	The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.	Astrazeneca
24900296	38	Sulfonate-Containing Thiiranes as Selective Gelatinase Inhibitors	TBA
20529685	70	MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.	Pfizer
20529684	112	Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.	Pfizer
20180536	128	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.	Universit£
20172725	49	Discovery and SAR of hydantoin TACE inhibitors.	Merck Research Laboratories
20022498	71	The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.	Schering-Plough Research Institute
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19908842	84	Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.	National Human Genome Research Institute
19703773	63	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.	Gsk Medicines Research Centre
19775099	184	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.	Universit£
19625186	59	3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.	Wyeth Research
19524436	27	Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group.	University of Shizuoka and Global Coe Program
19725580	93	Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.	Wyeth Research
19606871	124	N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.	Universit£
18835710	69	Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.	Schering-Plough Research Institute
19410464	71	Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.	Wyeth Research
19329309	49	Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.	Wyeth Research
19053764	101	Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.	Instituto Superior TéCnico
18945617	50	Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.	Pfizer
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University of Athens
18782669	90	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.	Université
17623656	34	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.	Pfizer
18029177	57	A novel series of highly selective inhibitors of MMP-3.	Pfizer
17591762	102	Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.	Pfizer
17531482	67	Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.	Wyeth Research
17512742	32	Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.	Université
17276676	112	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17088065	106	alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.	Università
17064892	123	Identification of potent and selective TACE inhibitors via the S1 pocket.	Wyeth Research
16723229	108	Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.	Wyeth Research
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16473009	23	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16420030	38	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.	Chinese Academy of Sciences
16392792	29	Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.	Aventis Pharma Deutschland
16153831	87	Synthesis and SAR of highly selective MMP-13 inhibitors.	Wyeth Research
16005220	52	Identification of potent and selective MMP-13 inhibitors.	Wyeth Research
15953722	56	Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.	Pfizer
15837315	13	A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.	Università
15780611	74	Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.	Pfizer
15324896	71	3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.	Pfizer
14711305	26	Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.	University of Athens
14684295	109	Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.	Chinese Academy of Sciences
12877590	28	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.	Pfizer
12408705	73	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.	Bristol-Myers Squibb
11958997	53	Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.	University of Bielefeld
11585440	76	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Dupont Pharmaceuticals
11563922	147	Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.	UniversitäT Bielefeld
11229774	40	Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).	Pfizer
11229773	73	Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.	Pfizer
27194201	164	Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors.	Eli Lilly
10411481	144	Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.	Cea
30522899	28	Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP).	Universit£
9548812	67	Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.	Kanebo
12713420	2	Callysponginol sulfate A, an MT1-MMP inhibitor isolated from the marine sponge Callyspongia truncata.	The University of Tokyo
30212201	17	Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing.	University of Notre Dame
29727184	56	Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies.	Universit£
28818461	67	Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.	Nestl�
30249495	241	Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.	Graz University of Technology
30034605	15	In Search of Selectivity in Inhibition of ADAM10.	University of Notre Dame
29028530	48	A pentanoic acid derivative targeting matrix metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line.	Jadavpur University
28558971	38	Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.	Merck
28653849	67	Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.	Scripps Florida
16206837	9	Tyrosinase inhibition: conformational analysis based studies on molecular dynamics calculations of bipiperidine based inhibitors.	University of Karachi
18355729	12	Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin.	University of Dundee